


# CLAIMS

1. A fused bicyclic pyrimidine derivative represented by the following general formula (1), or a salt thereof:




wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C<sub>1</sub> to C<sub>6</sub> alkyl group, which may be substituted with a halogen atom, and a C<sub>1</sub> to C<sub>6</sub> alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C<sub>1</sub> to C<sub>6</sub> alkyl group, a hydroxyl group, a C<sub>1</sub> to C<sub>6</sub> alkoxy group, a formyl group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkylcarbamoyl group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl group, an amino

group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a  
 5 substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of  
 10 a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms;

m is 1 or 2; and

n is 2 or 3.

2. The fused bicyclic pyrimidine derivative according to  
 15 claim 1 represented by the following general formula (1a), or a salt thereof:




wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one  
 20 another to form a ring) that are each independently selected

from the group consisting of a halogen atom, a C<sub>1</sub> to C<sub>6</sub> alkyl group, which may be substituted with a halogen atom, and a C<sub>1</sub> to C<sub>6</sub> alkoxy group ;

the ring C is a 5- to 7-membered nitrogen-containing ring,  
5 which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C<sub>1</sub> to C<sub>6</sub> alkyl group, a hydroxyl  
10 group, a C<sub>1</sub> to C<sub>6</sub> alkoxy group, a formyl group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkyl carbamoyl group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl group, an amino group, a mono- or di-substituted C<sub>1</sub> to C<sub>6</sub> alkylamino group, a  
15 C<sub>1</sub> to C<sub>6</sub> alkylcarbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkoxy carbonylamino group, a C<sub>1</sub> to C<sub>6</sub> alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




20 wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms; and


n is 2 or 3.

3. The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented either by the following

5 formula:




wherein R¹ is a hydroxyl group, a C1 to C6 alkoxy group, a formyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C1 to C6 alkylcarbamoyl group, an amino group, a mono- or di-substituted C1 to C6 alkylamino group, a C1 to C6 alkylcarbonylamino group, a C1 to C6 alkoxy carbonylamino group, a C1 to C6 alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent  
15 represented by the following formula:



wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of  
20 a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.


4. The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula

(1a), the ring C is represented by the following formula:




wherein X is -O- or -S(O)<sub>q</sub>-; and q is 0, 1, or 2.

5. The fused bicyclic pyrimidine derivative according to  
5 claim 2, or a salt thereof, wherein in the general formula  
(1a), the ring C is a functional group represented by the  
following formula:




wherein R<sup>2</sup> is a hydrogen atom, a C<sub>1</sub> to C<sub>6</sub> alkyl group, a  
10 formyl group, a C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl group, a C<sub>1</sub> to C<sub>6</sub>  
alkoxycarbonyl group, a carbamoyl group, a mono- or di-  
substituted C<sub>1</sub> to C<sub>6</sub> alkylcarbamoyl group or a C<sub>1</sub> to C<sub>6</sub>  
alkylsulfonyl group; and r is 1 or 2.

6. The fused bicyclic pyrimidine derivative according to  
15 claim 2, or a salt thereof, wherein in the general formula  
(1a), the ring C is represented by the following formula:



wherein R<sup>2'</sup> is an acetyl group or a methylsulfonyl group;  
and r is 1 or 2.

20 7. The fused bicyclic pyrimidine derivative according to  
claim 2, or a salt thereof, wherein the ring C in the general  
formula (1a) is represented by the following formula:



8. The fused bicyclic pyrimidine derivative according to claim 7, or a salt thereof, wherein in the general formula (1a) above, n is 3.
- 9 The compound according to claim 1, wherein the compound represented by the general formula (1) is 9-(4-acetylpiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.
- 10 10. The compound according to claim 1, wherein the compound represented by the general formula (1) is 5-[3,5-bis(trifluoromethyl)benzyl]-9-(1,1-dioxothiomorpholine-4-yl)-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.
- 15 11. The compound according to claim 1, wherein the compound represented by the general formula (1) is 9-(4-acetylhomopiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.
- 20 12. The compound according to (I), wherein the compound represented by the general formula (1) is 5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-9-(4-methylpiperazine-1-yl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

13     A tachykinin receptor antagonist containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 12 or a salt thereof.

14.     An NK1 receptor antagonist containing as an active  
5 ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 7, or a salt thereof.

15.     A prophylactic or therapeutic agent for dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine, containing as an  
10 active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 12, or a salt thereof.

16.     A prophylactic or therapeutic agent for disorders of digestive tract such as ulcerative colitis and Crohn's disease, containing as an active ingredient the fused bicyclic  
15 pyrimidine derivative according to any one of claims 1 through 12, or a salt thereof.

17.     A prophylactic or therapeutic agent for vomiting induced by exposure to X-ray, chemotherapy, pregnancy, migraine, postoperative pains, decreased gastrointestinal motility, and  
20 side effects of drugs, containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 12, or a salt thereof.

18.     A therapeutic agent for treating conditions, such as  
25 asthma, coughing, ache, migraine, tooth pain, and rheumatoid

arthritis, containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 12, or a salt thereof.